JOLT Health Inc. Announces Issuance Of Common Shares In Satisfaction Of Interest Payments To Promissory Note Holders And Interest Payment To Convertible Debenture Holder


(MENAFN- GlobeNewsWire - Nasdaq)

VANCOUVER, BC, CANADA, May 25, 2023 (GLOBE NEWSWIRE) -- Jolt health Inc. (formerly Love Pharma Inc.) (“Jolt” and or“the Company”) (CSE:JOLT) (FSE: G1Q0) is pleased to announce that pursuant to a 10% interest bearing convertible debenture issued on October 12, 2022, the Issuer issued a total of 13,765,763 common shares, at $0.015 per common share in satisfaction of the aggregate interest payment owed by the Issuer of $195,000 to a Debenture holder In addition, pursuant to Promissory Notes dated January 23, 2020 and extended to December 31, 2023, the Issuer issued a total of 6,116,913 common shares at $0.15 per common share in satisfaction of the aggregate per annum interest rate of 5% owing on the Promissory Notes.

The common shares are being issued to arms-length parties, and are subject to a four month hold period. The shares for debt settlement is subject to the approval of the Canadian Securities Exchange.

About Jolt Health Inc .

With a focus on the global sexual Health and Wellness markets, Jolt Health Inc., formerly Love Pharma Inc. (CSE:JOLT) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Jolt holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

MENAFN25052023004107003653ID1106319668


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.